High predicted durability for the novel small-diameter OmniaSecure defibrillation lead

Area of Science:

• Cardiovascular medicine
• Biomedical engineering
• Medical device technology

Background:

• Implantable cardioverter-defibrillator (ICD) leads are a critical component, yet lead failure remains a concern.
• Increasing patient longevity and ICD battery life necessitate more durable defibrillation leads.
• The LEADR trial introduced the OmniaSecure lead, a small-diameter, lumenless design, showing initial safety and efficacy with no fractures in early follow-up.

Purpose of the Study:

• To project the 10-year fracture-free survival rate of the OmniaSecure defibrillation lead.
• To utilize advanced reliability modeling to predict long-term lead performance.
• To compare projected durability against existing lead technologies.

Main Methods:

• Employed a validated reliability model integrating patient data and bench testing results.
• Assessed lead bending curvature in vivo using biplane fluoroscopy during patient and cardiac motion.
• Conducted bench tests simulating in vivo conditions with exaggerated bending to determine lead fatigue strength.

Main Results:

• Reliability modeling predicts a 98.2% fracture-free survival rate for the OmniaSecure lead at 10 years.
• The projected 10-year fracture-free survival rate in adolescents is 97.9%.
• These projections surpass the modeled and clinical 10-year performance of the larger Sprint Quattro lead.

Conclusions:

• Modeling indicates the OmniaSecure lead possesses high projected durability for 10-year performance.
• The lead's reliability is particularly promising for the active adolescent pediatric population.
• The novel 4.7F defibrillation lead is designed for enhanced reliability, addressing a clinical need.